Skip to main content
Signal8

LIPELLA PHARMACEUTICALS INC. (LIPO)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Lipella Pharmaceuticals Inc. logo

Lipella Pharmaceuticals Inc.

OTC:LIPOHealthcare
$0.0006
CLOSED
Mkt Cap$3K
EV-
Float4.4M
O/S4.62M
VOL43K sh
$ Vol$26
RVOL5.50×
Inst Own-
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 11, 20260.00060.00060.00060.000643,343
Nov 4, 20260.00050.00050.00050.0005645
Oct 28, 20260.00060.00060.00060.0006353
Oct 26, 20260.00050.00050.00050.00051,682
Oct 23, 20260.00050.00050.00050.0005915
Oct 20, 20260.00050.00050.00050.0005310
Oct 16, 20260.00050.00050.00050.0005400
Oct 12, 20260.00060.00060.00060.0006236
Oct 9, 20260.00050.00050.00050.0005300
Oct 7, 20260.00050.00050.00050.00052,894
Oct 2, 20260.00050.00050.00050.0005594
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
Insider Trades
InsiderTypeShares
Kaufman Jonathan H profile photoKaufman Jonathan HOther125.8K
Kaufman Jonathan H profile photoKaufman Jonathan HOther4.1K
Kaufman Jonathan H profile photoKaufman Jonathan HOther28.9K
Kaufman Jonathan H profile photoKaufman Jonathan HOther537.0K
Kaufman Jonathan H profile photoKaufman Jonathan HOther10.3K
Kaufman Jonathan H profile photoKaufman Jonathan HOther4.1K
Shareholders
0.0%
Institutional
(0)
0.0%
Insiderⓘ
(0)
12.1%
5%+ Owners
(5)
of which 0.1% rests on schedules older than 24 months (1 holder)
87.9%
Unattributed (incl. retail)ⓘ
5%+ Beneficial12.1%
Unattributed (incl. retail)87.9%
Top Shareholders
NameShares%
Jonathan H. Kaufman logo
Jonathan H. Kaufman
· may incl. warrants· filed Apr 2025
212.3K4.6%
Michael B. Chancellor logo
Michael B. Chancellor
· may incl. warrants· filed Apr 2025
209.6K4.5%
Leaf Huang logo
Leaf Huang
· may incl. warrants· filed May 2025
69.4K1.5%
SABBY MANAGEMENT, LLC logo
SABBY MANAGEMENT, LLC
· may incl. warrants· filed Jan 2025
60.3K1.3%
Michele Gruber logo
Michele Gruber
· may incl. warrants· stale · filed Nov 2024
5.9K0.1%
Sources: 13D/13GO/S: 4.6M · as of 13 Nov 2025 · SEC filings
Insiders & Institutional Holders

Insiders

About

Lipella Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the creation of novel therapies.

The company achieves this by repurposing and optimizing the active ingredients found in established generic drugs, tailoring these reformulations for diverse medical applications.

Its lead candidate, LP-10, a tacrolimus formulation, is presently in Phase IIa clinical studies, targeting radiation-induced hemorrhagic cystitis.

Additionally, LP-310, another tacrolimus-derived compound, is under development for the management of oral lichen planus. Founded in 2005, the company maintains its headquarters in Pittsburgh, Pennsylvania.

Key Metrics
Market Cap$2,773
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership-

No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateDec 19, 2022
Shares Outstanding4.62M
Authorized Shares
Float4.40M
52-Week Range
$0.0002$0.5420
$0.0006(0th percentile)
Volume
Average Daily Volume7.88K
43.34K today vs 7.88K avg(+450%)

30d Avg

7.88K

60d Avg

3.81K

90d Avg

3.88K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of LIPO as of Sep 30, 2025 records an effective S-3 shelf registration (effective Apr 3, 2025), an at-the-market sales agreement dated Apr 4, 2025, 7 outstanding warrant series and a PIPE closed Mar 17, 2025, from SEC filings. Lipella Pharmaceuticals Inc. (OTC: LIPO) traded at $0.0006 on Nov 11, 2026. 52-week range: $0.0002 to $0.5420. The company is in the Healthcare sector (Biotechnology).